Please assess the completion status of the following clinical trial:

Trial Title: Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have relapsed or refractory MM treated with at least 1 prior regimen. Prior therapy with bortezomib is allowed if there was previously at least a minimal response (MR).~* Have measurable disease as defined by one or more of the following:~  * serum M-protein concentration ≥ 1 g/dL (10 g/L)~ * urine monoclonal light chain concentration ≥ 200 mg/24 hours as determined by urine protein electrophoresis~ * involved serum free light chain (SFLC) concentration ≥ 10 mg/dL (100 mg/L) and an abnormal SFLC ratio~* Have adequate organ function including:~  * Absolute neutrophil count (ANC) ≥ 1000/microliter~ * Platelet (PLT) count ≥ 75,000/microliter~ * Hemoglobin (Hgb) ≥ 8.0 g/dL~ * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (if total is elevated check direct and, if normal, participant is eligible)~ * Aspartate transaminase (AST) and alanine aminotransferase (ALT) are ≤ 3 x ULN~ * Serum creatinine ≤ 3.0 mg/dL.~* Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of ≤ 2.~* Have discontinued all previous therapies for cancer, including chemotherapy, surgery, and radiotherapy for at least 2 weeks (6 weeks for mitomycin-C or nitrosoureas) before study enrollment and recovered from the acute effects of therapy.~* Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for 4 months following the last dose of study drug.~* Females with childbearing potential: Must have had a negative urine or serum pregnancy test \<7 days before the first dose of study drug.~* Have an estimated life expectancy of ≥16 weeks, in the opinion of the investigator.~Exclusion Criteria:~* Have received treatment within 30 days of the initial dose of study drug with an experimental agent for non-cancer indications that has not received regulatory approval for any indication.~* Have one or more serious preexisting medical conditions that, in the opinion of the investigator, would preclude participation in this study.~* Have an uncontrolled infection.~* Females who are pregnant or breastfeeding.~* Have known positive test results for human immunodeficiency virus (HIV), hepatitis B\*, or hepatitis C antibodies (HCAb).~  \* Have evidence of or test positive for hepatitis B. A positive test for hepatitis B is defined as:~ 1. positive for hepatitis B surface antigen (HBsAg+). OR~ 2. positive for anti-hepatitis B core antibody and positive for hepatitis B deoxyribonucleic acid (HBV DNA).~     OR~ 3. positive for anti-hepatitis B surface antibody (HBsAb+) and positive for hepatitis B deoxyribonucleic acid (HBV DNA).~* Have ≥ Grade 2 peripheral neuropathy or any grade with pain as assessed using the Common Terminology Criteria for Adverse Events, version 4.03 (CTCAE v 4.03).~* Have previously received an allogenic hematopoietic stem cell transplant.~* Have previously received treatment with an experimental agent that targets B-cell activating factor (BAFF).~* Have a corrected QT (QTc) interval \>470 msec on their baseline electrocardiogram (ECG).~* Have interstitial pneumonitis (interstitial pneumonia) or pulmonary fibrosis manifested as opacity on chest X-ray or computed tomography (CT) scan.~* Have had another active malignancy within the past 5 years.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex) (Type: EXPERIMENTAL): Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m\^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
- 300 mg Tabalumab+BTZ IV+Dex (Type: EXPERIMENTAL): Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
- 300 mg Tabalumab+BTZ SC+Dex (Type: EXPERIMENTAL): Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m\^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete